Biotechnology

Taysha Gene Therapies

Taysha Gene Therapies released FY2026 Q1 earnings on May 6 Pre-Market EST, actual revenue USD 0 (forecast USD 758.33 K), actual EPS USD -0.1199 (forecast USD -0.0958)

Taysha Gene Therapies to release FY2026 Q1 earnings on May 6 Pre-Market EST, forecast revenue USD 758.33 K, EPS USD -0.0958

Taysha Gene Therapies released FY2025 Q4 earnings on March 19 Pre-Market EST, actual revenue USD 5.485 M (forecast USD 1.889 M), actual EPS USD -0.0779 (forecast USD -0.0961)

Taysha Gene Therapies released FY2025 earnings on March 19 Pre-Market (EST), actual revenue USD 9.773 M (forecast USD 6.301 M), actual EPS USD -0.3409 (forecast USD -0.3628)

Taysha Gene Therapies to Release FY2025 Annual Earnings on March 19, 2026 Pre-Market EST, Forecast Revenue USD 6.301 M, EPS USD -0.3628

Taysha Announces Progress in TSHA-102 Gene Therapy Candidate for Rett Syndrome Treatment

Analysts Give Taysha Gene Therapies Strong Buy Rating

Taysha Gene Therapies released FY2025 9 Months Earnings on November 4 During-Market EST, Actual Revenue: USD 4.288 M, Actual EPS: USD -0.2627

Taysha Gene Therapies released FY2025 Q3 earnings on November 4 During-Market EST, actual revenue USD 0 (forecast USD 1.381 M), actual EPS USD -0.0926 (forecast USD -0.0884)

Taysha Gene Therapies revises sales agreement and regains full rights to Rett syndrome project

Taysha Gene Therapies Reports Q3 Operational Expenses at $34.024 Million, EPS at -$0.09

Taysha Gene Therapies to Release FY2025 Q3 Earnings on November 4 During-Market EST, Forecast Revenue USD 1.381 M, EPS USD -0.0884

Raymond James Gives Taysha Gene Therapies Inc. a Strong Buy Rating

Taysha Gene Therapies Maintains Buy Rating from Analysts

Gil Blum Maintains Buy Rating for Taysha Gene Therapies

Taysha Gene Therapies Receives Buy and Hold Ratings

Taysha Gene Therapies Receives Multiple Analyst Ratings

Analysts Reiterate Hold Rating on Taysha Gene Therapies

Taysha Gene Therapies released FY2025 Semi-Annual earnings on August 12 Pre-Market (EST), actual revenue USD 4.288 M, actual EPS USD -0.1706

Taysha Gene Therapies released FY2025 Q2 earnings on August 12 Pre-Market EST, actual revenue USD 1.986 M (forecast USD 1.605 M), actual EPS USD -0.0902 (forecast USD -0.0808)

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

TSHA

ARKG

LABU

SBIO

Taysha Gene Therapies, Inc. (TSHA) held its Q1 earnings call, highlighting strong clinical momentum for its Rett syndrome program TSHA-102. The company reported positive FDA interactions regarding a potential BLA pathway and ongoing clinical trials. Taysha's cash position stands at $276.6 million, sufficient to fund operations into 2028. However, R&D expenses surged to $33.8 million, leading to a net loss of $42.4 million. Approval timelines remain uncertain, with the FDA's requirements for data still fluid, impacting investor sentiment.

Tip Ranks

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average "Buy" recommendation from thirteen analysts. One analyst rated it as a sell, while ten rated it as a buy and two as a strong buy. The average 1-year price target is $11.64. Recent reports show price target increases from Canaccord Genuity and Needham & Company. Insider Sukumar Nagendran sold 200,000 shares, reducing his stake by 14.97%. Institutional investors hold 77.70% of the stock. TSHA opened at $6.81, with a market cap of $1.96 billion and a 1-year price range of $2.06 to $7.30.

Market Beat

Neurogene

Truist Financial

Marex

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by Brokerages

Taysha Gene Therapies (NASDAQ:TSHA) reported regulatory progress and ongoing clinical enrollment for its Rett syndrome gene therapy candidate TSHA-102 during its Q1 2026 earnings call. The company noted a wider year-over-year net loss due to increased development and manufacturing activities. CEO Sean Nolan discussed the FDA's feedback on a potential BLA submission based on six-month interim data. Taysha is on track with its REVEAL pivotal trial and plans to report longer-term data from treated patients. Manufacturing processes are being validated to support future submissions.

iShares Global Healthcare

VG Health

Health Care Select Sector SPDR

iShares US Pharma

Taysha Gene Therapies Q1 Earnings Call Highlights

Chardan Capital's Geulah Livshits has reiterated a Buy rating on Taysha Gene Therapies (TSHA) with a price target of $12.00. Livshits, who focuses on the Healthcare sector, has an average return of 12.6% and a 38.09% success rate on stock recommendations. Taysha Gene Therapies holds a Strong Buy consensus among analysts, with a price target consensus of $12.44.

Palvella Therapeutics

Iovance Biotherapeautics

Rocket Pharma

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)

Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)

Earnings Watch

Taysha Gene Therapies | 8-K: FY2026 Q1 Revenue: USD 0

Taysha Gene Therapies (NASDAQ:TSHA) is set to release its Q1 2026 earnings on May 6, with analysts predicting a loss of $0.10 per share and revenue of $0.756 million. The company previously reported a loss of $0.08 per share for Q1 2025, exceeding expectations. TSHA's stock is currently down 0.9%, with a market cap of $1.82 billion. Recent analyst ratings include a mix of buy and hold recommendations, with an average target price of $11.64. Insider trading activity shows a significant sale by an executive, while institutional ownership stands at 77.70%.

BNP Paribas

CAITONG SECURITIES

Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday

Taysha Gene Therapies, a biotech company trading as TSHA on Nasdaq, will be releasing their financial results for the first quarter of 2026 on May 6, 2026. The company, specializing in AAV-based gene therapies for severe monogenic CNS diseases, will also conduct a corporate update conference call and webcast at 8:30 AM Eastern Time. This announcement was made on April 29, 2026, from Dallas.

Unusual Whales

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

Taysha Gene Therapies(TSHA.US)